Transcatheter interventions have become a mainstay in cardiac care as treatments for structural and congenital heart ...
Beyond measuring blood flow, pressure, oxygen levels and other vital signs in the cardiac catheterization lab, current ...
Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease, but it caused almost as many major bleeds and there was no effect on cancers. These are the late-breaking findings presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2018, Aug. 25-28 in Munich, Germany, and published in the New England Journal of Medicine.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
The use of invasive, pressure wire-based fractional flow reserve (FFR) in the cath lab is now considered the gold ...
Biotronik announced it is now the exclusive U.S. distributor for the MoMe Kardia external cardiac diagnostic monitor from digital health company InfoBionic. The device benefits patients suspected of experiencing cardiac arrhythmias.
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to lower their risk, according to late-breaking results from the ARRIVE study. Results from ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2018, Aug. 25-28 in Munich, Germany, with simultaneous publication in The Lancet.1
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD) in diabetes mellitus (DM) patients, a patient population in which PAD prevalence has traditionally been difficult to assess. Researchers believe these findings, presented at the 2018 European Society of Cardiology (ESC) Congress, Aug. 25-28 in Munich, Germany, could lead to early identification of PAD and improve patient clinical outcomes, as well as prevent patients without PAD from undergoing unnecessary, expensive and invasive tests.
September 4, 2018 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...
Philips announced it has acquired Xhale Assurance Inc., a U.S.-based scale-up company developing and commercializing next-generation sensor technologies. Xhale Assurance’s disposable pulse oximetry sensor is placed on the wing (ala) of the nose, and can reliably measure and transmit a patient’s heart rate and blood oxygenation under low-perfusion conditions that are challenging for conventional fingertip pulse oximetry sensors. Philips said this technology will broaden and differentiate its existing portfolio of oxygen saturation monitoring solutions and allow the company to expand into a currently underserved clinical segment. Financial details of the transaction were not disclosed.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
A new report from data and analytics company GlobalData suggests that Amazon is poised to make huge strides in healthcare as the Internet retail giant prepares to enter a new market. The report highlights a business model that facilitates easier connectivity between providers and patients, a powerful online platform and its artificial intelligence (AI) interface, Alexa.
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI 61 trial. Results were presented in a Hot Line Session at the 2018 European Society of Cardiology (ESC) Congress, Aug. 25-28 in Munich, Germany, and published in the New England Journal of Medicine.
Use of an oral anticoagulant in medically ill patients for 45 days following hospital discharge reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial. The results were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2018, Sept. 25-28 in Munich, Germany, and published in The New England Journal of Medicine.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Behnam Tehrani, M.D., FSCAI, director of the cardiac cath lab, INOVA Heart and Vascular Institute, Fairfax, Va ...
This is a 360 degree photo view inside the neuro-interventional radiology lab at Henry Ford Hospital to show the layout ...
At the 2018 European Society of Cardiology (ESC) Congress, cardiovascular technology startup Maisense debuted the Freescan telecardiology system that uses a portable device to measure blood pressure and record electrocardiogram (ECG) readings simultaneously.